Editorial: Peptidases as a therapeutic target in anti-cancer management

Ana Mitrović; Roberta E Burden; Adaleta Softič; Nežka Kavčič

doi:10.3389/fphar.2024.1394018

Editorial: Peptidases as a therapeutic target in anti-cancer management

Front Pharmacol. 2024 Apr 11:15:1394018. doi: 10.3389/fphar.2024.1394018. eCollection 2024.

Authors

Ana Mitrović^{1

2}, Roberta E Burden³, Adaleta Softič⁴, Nežka Kavčič⁵

Affiliations

¹ Department of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia.
² Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
³ School of Pharmacy, Medical Biology Centre, Queen's University Belfast, Belfast, United Kingdom.
⁴ University of Tuzla, Tuzla, Bosnia and Herzegovina.
⁵ International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.

No abstract available

Keywords: ADAM17; anti-tumor treatment; cancer; cathepsins; peptidases; sentrin specific-protease; ubiquitin specific protease.

Publication types

Editorial

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by Slovenian Research and Innovation Agency [grant number J3-3071 to AM].